However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
News|Articles|April 8, 2025
Q1 2025 Recap: Pulmonology News and Updates
Author(s)Victoria Johnson
Fact checked by: Tim Smith
Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:
Advertisement
Advertisement
Pulmonology continues to evolve rapidly, driven by innovation in rare disease treatment, inhaled therapies, and personalized approaches to respiratory care. In the past few months, progress has extended across high-burden conditions like COPD and asthma, with new candidates showing promise where options have long been limited.
Related to this article
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Advertisement
Advertisement